NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Head & neck: Nasopharyngeal carcinoma — chemoRT

Free question published 15 September 2026

Head & neckNasopharyngeal carcinoma — chemoRT

A 41-year-old man of southern Chinese descent has non-keratinising nasopharyngeal carcinoma with bilateral cervical nodes, staged UICC TNM 8 T3 N2 M0 (stage III). He has performance status 0, normal renal function and normal hearing. What is the most appropriate primary treatment?

  1. AIMRT with concurrent cisplatin
  2. BInduction gemcitabine-cisplatin, then IMRT with concurrent cisplatin
  3. CIMRT alone
  4. DIMRT with concurrent cetuximab
  5. EInduction gemcitabine-cisplatin, then IMRT with concurrent cetuximab

Why B is correct

Intensity-modulated radiotherapy is the standard of care, and chemoradiotherapy is recommended for stage III disease. Current UK guidance adds that induction chemotherapy should be considered for all patients with high-risk locoregionally advanced nasopharyngeal carcinoma, such as this fit patient with T3 disease and bilateral N2 nodes. In a randomised phase 3 trial, three cycles of induction gemcitabine and cisplatin before concurrent cisplatin chemoradiotherapy improved recurrence-free and overall survival compared with chemoradiotherapy alone, with more acute grade 3–4 adverse events but similar late toxicity. NICE NG36 (2016) recommends IMRT with concomitant chemotherapy for stage 2 and above; the later trial evidence adds induction chemotherapy for high-risk disease.

And why the others are not

  • AWrong — concurrent cisplatin with IMRT is the backbone, but for high-risk locoregionally advanced disease adding induction gemcitabine-cisplatin improved recurrence-free and overall survival compared with chemoradiotherapy alone.
  • CWrong — chemoradiotherapy is recommended for stage II (except T2N0), stage III and stage IVa disease; radiotherapy alone is for early T1–T2 N0 disease, and chemoradiotherapy was superior to radiotherapy alone for progression-free and overall survival in advanced disease.
  • DWrong — this omits induction chemotherapy, and cetuximab has been shown to be inferior to cisplatin with radiotherapy; this patient is fit for cisplatin.
  • EWrong — the induction trial used concurrent cisplatin, and cetuximab has been shown to be inferior to cisplatin with radiotherapy; this patient is fit for cisplatin.

Source Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma — randomised trial — Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, Qin G, Kong X, Mo Y, Zhang R, Liu Z, Xie Y, Ruan X, Jiang W. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2024;10(4):456-463.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing